ArticleUpdates in surgery2025
Germline mutations of GCM2 cause a novel variant of hereditary primary hyperparathyroidism.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial transcriptomic analysis of mouse parathyroid gland cells expressing an activating variant ofJBMR plus · 2025Article
- Precision stratified treatment of primary hyperparathyroidism based on multilevel emerging biomarkers.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperparathyroidism (pHPT) occurs as hereditary disease in approximately 10% of cases. GCM2 germline mutations have been recently described as responsible for the development of a novel variant of hereditary pHPT. This study aimed to determine the features of GCM2-related pHPT. Demographics, laboratory, and surgical data were assessed in a series of 17 index cases carrying GCM2 mutations undergoing surgery for pHPT. The GCM2 germline pathogenic variant c.1181 A>C p.(Tyr394Ser) was detected in 59% of cases. GCM2-related pHPT was diagnosed at a median age of 57 years (range 32-82) with a Female/Male ratio 1.8. Preoperative median calcemia was 2.89 mmol/L (range 2.69-3.8). Family history of pHPT was absent in 65% of cases. Complete clinical, surgical and follow-up data were available for 13 patients. At initial surgery, bilateral neck exploration with subtotal parathyroidectomy was performed in 46% of patients; achieving cure in all cases at a median follow-up of 51 months (range 7-60). In the remaining cases undergoing selective parathyroidectomy, a persistent pHPT occurred in 3 cases; recurrent pHPT in 1 patient (after a disease-free interval of 4 years) while 3 are disease free at a mean follow-up of 21 months. Thus, at an overall prolonged follow-up (median 48 months, range 7-216), multiglandular involvement occurred in 77% of cases. GCM2 germline mutations may cause hereditary pHPT, even if it may mimic sporadic variant due to the absence of familial history and late onset. The main feature is multiglandular involvement, needing bilateral neck exploration and subtotal parathyroidectomy to achieve long-term cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.